Eli Lilly and Company $LLY Shares Sold by Facet Wealth Inc.

by · The Cerbat Gem

Facet Wealth Inc. cut its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 33.8% during the fourth quarter, Holdings Channel reports. The firm owned 2,001 shares of the company’s stock after selling 1,021 shares during the period. Facet Wealth Inc.’s holdings in Eli Lilly and Company were worth $2,049,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. ST Germain D J Co. Inc. increased its holdings in shares of Eli Lilly and Company by 3.4% in the fourth quarter. ST Germain D J Co. Inc. now owns 1,756 shares of the company’s stock valued at $1,887,000 after purchasing an additional 57 shares during the period. LCM Capital Management Inc acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $224,000. High Point Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $59,000. Sanctuary Advisors LLC increased its holdings in shares of Eli Lilly and Company by 3.1% in the fourth quarter. Sanctuary Advisors LLC now owns 244,134 shares of the company’s stock valued at $262,365,000 after purchasing an additional 7,349 shares during the period. Finally, Quent Capital LLC increased its holdings in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Quent Capital LLC now owns 5,542 shares of the company’s stock valued at $5,956,000 after purchasing an additional 144 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on LLY shares. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Monday, April 6th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $875.00 to $880.00 and gave the stock a “neutral” rating in a report on Friday, April 10th. Leerink Partners dropped their target price on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Berenberg Bank raised their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,216.52.

Read Our Latest Research Report on Eli Lilly and Company

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: Large AI gene‑editing partnership with Profluent (up to $2.25B) broadens Lilly’s digital biology and next‑generation genetic medicine pipeline, a long‑term growth and valuation positive. Read More.
  • Positive Sentiment: Acquisition of Ajax Therapeutics (up to $2.3B) adds a JAK2 myelofibrosis program and deepens oncology exposure — complementary to recent M&A and supports analyst bullishness. Read More.
  • Positive Sentiment: Analyst support and price‑target moves (e.g., Guggenheim raise) reflect confidence that acquisitions plus pipeline execution justify upside vs. the pullback. This can underpin buying interest if Q1 execution meets expectations. Read More.
  • Neutral Sentiment: Wall Street forecasts strong Q1 revenue growth (~36–37%) and investors expect pipeline commentary; earnings results and management commentary will be the immediate catalyst for intraday moves. Read More.
  • Neutral Sentiment: Options and trader models imply sizable post‑earnings volatility — the report could drive a sharp move either way, so risk around the print is elevated. Read More.
  • Negative Sentiment: Early launch data show Foundayo prescriptions lagging a Novo rival and social chatter flags a slow oral GLP‑1 rollout; weaker uptake puts short‑term pressure on growth expectations for obesity franchise. Read More.
  • Negative Sentiment: Canada approved cheaper generic weight‑loss drugs, highlighting accelerating competitive and pricing risks in the GLP‑1 market that could weigh on sales mix and margins over time. Read More.
  • Negative Sentiment: Notable insider selling activity and some fund/portfolio churn reported recently; heavy sales can be perceived negatively by sentiment‑driven investors ahead of the quarter. Read More.

Eli Lilly and Company Stock Down 2.6%

Eli Lilly and Company stock opened at $851.65 on Thursday. The firm has a market cap of $804.65 billion, a price-to-earnings ratio of 37.11, a price-to-earnings-growth ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The business’s 50-day moving average price is $948.77 and its 200 day moving average price is $985.31. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).